Clinical Trials
16 trialsNCT01351545 2026-06-04
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
Recruiting
NCT05800210 2026-06-04
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
Phase 2 Recruiting
NCT06131801 2026-06-04
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
Recruiting
NCT06904066 2026-06-04
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05143840 2026-06-02
ALERTCML
University of Alabama at Birmingham
Phase 2 Recruiting
NCT05334069 2026-06-02
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
Recruiting
NCT07527221 2026-06-01
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Phase 1 Recruiting
NCT04195633 2026-05-29
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07354074 2026-05-26
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT02115295 2026-05-20
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06817720 2026-05-20
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03326921 2026-05-18
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT06236724 2026-05-15
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07549516 2026-05-15
ASC2ADHERE
Novartis
Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting